Sevelamer carbonate - Sanofi
Alternative Names: GZ 419831; RenvelaLatest Information Update: 31 Mar 2022
Price :
$50 *
At a glance
- Originator Genzyme Corporation
- Developer Sanofi
- Class Antihyperglycaemics; Chlorinated hydrocarbons; Epoxy compounds; Hyperphosphataemia therapies; Polyamines; Small molecules
- Mechanism of Action Chelating agents; Phosphate binding protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hyperphosphataemia
Most Recent Events
- 16 Aug 2019 Sanofi completes the phase III RECOVER trial for Hyperphosphataemia in China (PO, Tablet) (NCT03001011)
- 21 Dec 2016 Sanofi plans the phase III RECOVER trial for Hyperphosphataemia in China (PO, Tablet) (NCT03001011)
- 01 Jun 2015 Genzyme completes a phase II trial in Hyperphosphataemia (In adolescents, In children, In infants) in Poland, Lithuania, Germany, France and USA (NCT01574326)